Page last updated: 2024-11-06

ibopamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ibopamine is a synthetic catecholamine derivative that was originally developed as a potential treatment for Parkinson's disease. It acts as a dopamine agonist, meaning it binds to and activates dopamine receptors in the brain. Ibopamine's mechanism of action is complex and involves both dopaminergic and non-dopaminergic effects. It is thought to increase dopamine levels in the brain by inhibiting the reuptake of dopamine and by stimulating dopamine release. Ibopamine has also been shown to have anti-inflammatory and neuroprotective effects. While promising in preclinical studies, ibopamine has not been approved for clinical use due to concerns about its potential side effects. Research on ibopamine has continued, with interest in its potential for treating other conditions such as Alzheimer's disease and addiction. However, the development of ibopamine has been hampered by its complex pharmacology and potential toxicity.'

ibopamine: structure given in UD 31;67a & in 2nd source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68555
CHEMBL ID307739
CHEBI ID135306
SCHEMBL ID147258
MeSH IDM0080783

Synonyms (37)

Synonym
CHEMBL307739
trazyl
sb-7505
ibopamine
4-[2-(methylamino)ethyl]benzene-1,2-diyl bis(2-methylpropanoate)
ibopamine (usan/inn)
D04488
66195-31-1
propanoic acid, 2-methyl-, 4-(2-(methylamino)ethyl)-1,2-phenylene ester
ibopamino [inn-spanish]
einecs 266-229-5
sb 7505
4-(2-(methylamino)ethyl)-2-phenylendiisobutyrat
skf 100168
ibopaminum [inn-latin]
4-(2-(methylamino)ethyl)-o-phenylene diisobutyrate
L013392
CHEBI:135306
[4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate
8zca2i2l11 ,
ibopamine [usan:inn:ban]
unii-8zca2i2l11
ibopaminum
ibopamino
4-[2-(methylamino)ethyl]-o-phenylene diisobutyrate
ibopamine [inn]
ibopamine [usan]
ibopamine [mart.]
ibopamine [who-dd]
ibopamine [mi]
SCHEMBL147258
DTXSID3023138
5-[2-(methylamino)ethyl]-2-[(2-methylpropanoyl)oxy]phenyl 2-methylpropanoate
Q5984366
DB13316
4-(2-(methylamino)ethyl)-1,2-phenylene bis(2-methylpropanoate)
sb 7505; sb 7505 (pharmaceutical); skf 100168

Research Excerpts

Overview

Ibopamine is a prodrug of epinine (deoxyepinephrine) that exhibits activity at dopaminergic and adrenergic receptors. Ibopamine has been shown to cause pupillary dilation and an increase in aqueous humour secretion.

ExcerptReferenceRelevance
"An ibopamine challenge is a novel technique for assessing glaucoma using ibopamine, a topical drug which temporarily increases aqueous production. "( Ibopamine challenge testing differentiates glaucoma suspect, stable glaucoma and progressive glaucoma cases.
Craig, JE; Landers, J; Ullrich, K, 2015
)
2.48
"Ibopamine is a prodrug of epinine (deoxyepinephrine) that exhibits activity at dopaminergic and adrenergic receptors. "( Effect of ibopamine on aqueous humor production in normotensive humans.
Brubaker, RF; Ciarniello, MG; Dionisio, P; Herman, DC; McLaren, JW; Nau, CB; Rosignoli, MT; Wayman, LL, 2003
)
2.16
"Ibopamine is a prodrug of N-methyldopamine that has a non-cycloplegic mydriatic action due to its alpha-adrenergic properties and is able to induce, when topically given, a transient increase of intraocular pressure (IOP) in eyes with hydrodynamic disorders."( The effects of 2% ibopamine eye drops on the intraocular pressure and pupil motility of patients with open-angle glaucoma.
Di Staso, S; Giuffrè, I; Taverniti, L,
)
1.91
"Ibopamine is a non-selective dopamine- and adrenalin-receptor agonist that has been shown to cause pupillary dilation and an increase in aqueous humour secretion. "( [Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine].
Iliev, ME; Windisch, BK, 2006
)
2.01
"Ibopamine is an alpha-adrenergic agent and causes an elevation of intraocular pressure in eyes with increased outflow resistance. "( [Positive ibopamine provocative test in normal-tension glaucoma suspects].
Gloor, BP; Kniestedt, C; Romppainen, T; Stürmer, J, 2007
)
2.18
"Ibopamine is an orally active dopamine agonist (DA) with both hemodynamic and neurohumoral properties in humans."( Effect of ibopamine on ventricular remodeling after experimental myocardial infarction: a comparison with captopril.
Buikema, H; de Graeff, PA; Hegeman, H; Lie, KI; Scholtens, E; van Gilst, WH; van Veldhuisen, DJ, 1994
)
1.41
"Ibopamine is an orally administered dopamine agonist which is rapidly converted to its active metabolite epinine by esterase hydrolysis. "( Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.
Faulds, D; Fitton, A; Spencer, C,
)
3.02
"Ibopamine is a dopaminergic mydriatic of proven use for fundoscopy. "( Ibopamine: a new preoperative mydriatic for cataract surgery.
Buckley, SA; Corbett, MC; Richards, AB,
)
3.02
"Ibopamine is an original dopamine analogue. "( Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent.
Galbiati, I; Gazzaniga, A; Gianesello, V; Soldati, L; Virno, M, 1993
)
1.97
"Ibopamine is an active dopamine analogue leading to improved renal perfusion and afterload reduction in heart failure. "( Ibopamine as a valuable adjunct and substitute for dopamine in bridging therapy before heart transplantation.
Cabell, B; Glogar, D; Kleber, FX; Sabin, GV; Thyroff-Friesinger, U, 1992
)
3.17
"Ibopamine is an selective dopamine agonist for oral use."( [New dopamine agonists in cardiovascular therapy].
Girbes, AR; Smit, AJ; Van Veldhuisen, DJ,
)
0.85
"Ibopamine is an orally active derivative of dopamine (DA) which metabolizes to its active form, epinine. "( Clinical pharmacology of ibopamine.
Itoh, H, 1991
)
2.03
"Ibopamine is a new, orally active drug with a predominant action on dopaminergic adrenoceptors."( Ibopamine in the treatment of heart failure.
Man in't Veld, AJ, 1991
)
2.45
"Ibopamine is a dopamine-like drug that shows mainly vasoactive properties, predominantly acting on dopamine1-(DA1-) and DA2-adrenoceptors. "( Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects.
López-Sendón, J, 1991
)
3.17
"Ibopamine (IP) is a novel dopamine analogue for which beneficial effects have been shown in chronic heart failure. "( [Ibopamine--acute hemodynamic, renal and neurohumoral effects].
Theisen, K; Wehling, M, 1991
)
2.63
"Ibopamine is a dopamine-related drug active by oral route, namely the diisobutyric ester of N-methyl-dopamine."( Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs.
Marchetti, GV, 1990
)
1.3
"Ibopamine is an orally active dopaminergic substance and acts mainly as a vasodilator in patients with heart failure."( Effect of ibopamine, a dopamine congener, on arrhythmias in heart failure.
Storstein, L, 1990
)
1.4
"Ibopamine is a new, orally active dopamine-like drug with inotropic and vasoactive properties. "( Hemodynamic and neurohumoral effects of ibopamine in patients with chronic congestive heart failure.
López-Sendón, J, 1990
)
1.99
"1. Ibopamine is a new orally active inodilator, which is developed for the treatment of congestive heart failure (CHF). "( Efficacy and safety of ibopamine in congestive heart failure.
Crijns, HJ; de Graeff, PA; Girbes, AR; Lie, KI; Smit, AJ; van Veldhuisen, DJ, 1990
)
1.21
"Ibopamine is a novel oral dopamine analogue with positive inotropy and diuretic effects. "( [Renal effects of ibopamine in comparison with furosemide in patients with mild heart failure].
Gerzer, R; Theisen, K; Wehling, M; Weil, J; Zimmermann, J, 1990
)
2.06
"Ibopamine is a novel oral dopamine analogue with vasodilatory, positive inotropic and diuretic effects. "( Extracardial effects of oral ibopamine versus furosemide in patients with mild or moderate heart failure. A double-blind, randomized trial.
Theisen, K; Wehling, M; Zimmermann, J, 1990
)
2.01
"Ibopamine is a dopaminergic and adrenergic receptor agonist, which is active in the treatment of congestive heart failure. "( Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study.
, 1989
)
2.09
"Ibopamine is a new orally active dopamine analogue with positive inotropic and vasodilating activity. "( Ibopamine: long-term safety study in patients with congestive heart failure. The Italian Ibopamine Working Group.
Abbondati, G; Cavalli, A; Cedrini, MC; Fuccella, LM; Riva, E; Schleman, M, 1989
)
3.16
"Ibopamine is an orally active derivative of dopamine which undergoes hydrolysis to the active moiety epinine. "( Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
Henwood, JM; Todd, PA, 1988
)
3.16
"Ibopamine is an orally effective derivative of dopamine capable of eliciting peripheral and renal vasodilating activity and positive inotropic action. "( Ibopamine--how should it be used?
Bussmann, WD; Frik, R; Wienhöfer, K, 1988
)
3.16
"Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated."( Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure.
Dei Cas, L; Manca, C; Metra, M; Nodari, S; Riva, S; Visioli, O, 1988
)
1.26

Effects

Ibopamine has shown no detrimental effects on renal function, few adverse effects on neurohormonal parameters and has demonstrated no significant proarrhythmic properties at therapeutic doses. Ibopamine is a safe and useful drug added to conventional treatment of cardiac heart failure.

ExcerptReferenceRelevance
"Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear. "( Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine.
Cas, LD; Metra, M; Missale, C; Spano, PF, 1995
)
1.95
"Ibopamine has varying degrees of affinity for these various families, being the highest for the dopamine receptors and the lowest for the alpha adrenergic receptors."( Neurohormonal and hemodynamic effects of ibopamine.
Pouleur, H, 1995
)
1.28
"Ibopamine has shown no detrimental effects on renal function, few adverse effects on neurohormonal parameters and has demonstrated no significant proarrhythmic properties at therapeutic doses in patients with congestive heart failure."( Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.
Faulds, D; Fitton, A; Spencer, C,
)
2.3
"Ibopamine has been shown to be a safe and useful drug added to conventional treatment of cardiac heart failure."( [Ibopamine in the treatment of congestive heart failure. Multicenter follow-up study].
Astorga, MA; Ceia, F; Coelho, EM; Fonseca, C; Gil, V; Gomes, RS; Gouveia, R; Luís, AS; Mota, E; Riva, E, 1992
)
1.92
"Ibopamine has proved to be safe in many thousands of heart failure patients during long-term therapy."( Ibopamine in the treatment of heart failure.
Man in't Veld, AJ, 1991
)
2.45
"Ibopamine has potential in improving prognosis by its major effects: vasodilatation, decrease in vasoactive hormones and improvement in renal blood flow and water diuresis."( [Ibopamine--clinical results].
Kleber, FX, 1991
)
1.91

Actions

Ibopamine is able to activate dopamine specific and adrenergic receptors in the heart and circulation, inducing a vasodilating activity. Ibopamine does not produce undesirable renal side effects, but affects the neurohumoral status favourably.

ExcerptReferenceRelevance
"Ibopamine seems to increase the risk of death among patients with advanced heart failure who are already receiving optimum therapy, but the reasons for this increase are not clear. "( Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.
Ardia, A; Block, P; Cortina, A; Cowley, AJ; Cserhalmi, L; Follath, F; Hampton, JR; Jensen, G; Kayanakis, J; Kleber, FX; Lie, KI; Mancia, G; Skene, AM; van Veldhuisen, DJ, 1997
)
2.03
"Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study."( Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure.
Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992
)
1.24
"Ibopamine is able to activate dopamine specific and adrenergic receptors in the heart and circulation, inducing a vasodilating activity together with a mild positive inotropic effect without increasing heart rate and myocardial O2 consumption."( Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs.
Marchetti, GV, 1990
)
1.3
"Ibopamine does not produce undesirable renal side effects, but affects the neurohumoral status favourably."( Extracardial effects of oral ibopamine versus furosemide in patients with mild or moderate heart failure. A double-blind, randomized trial.
Theisen, K; Wehling, M; Zimmermann, J, 1990
)
1.29
"Ibopamine had a slower but more prolonged effect on cardiac output (increase of up to 32.1% at 60 min) and systemic vascular resistances."( Onset of cardiovascular action after oral ibopamine. Early hemodynamic effects of single and repeated doses in patients with idiopathic dilated myocardiopathy.
Compostella, L; Cucchini, F; Di Mario, C; Ghirardi, P; Iavernaro, A; Libardoni, M, 1990
)
1.26
"Ibopamine caused an increase in mean estimated stroke volume (SV +29% for the maximum change from baseline and +15% cumulatively over the first h) with no change in mean heart rate (HR) or QTc."( Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man.
Brendel, E; de Mey, C; Enterling, D; Wesche, H, 1988
)
1.24

Treatment

Ibopamine treatment was ineffective in Group 2, while in Group 1 patients there was a statistically significant increase in creatinine clearance (+23% after 3 months, +31% after 6 months). Ibopamine-treatment, which resulted in peak plasma epinine concentrations of 4-5 nmol.l-1, neither affected resting heart rate or blood pressure.

ExcerptReferenceRelevance
"Ibopamine treatment was ineffective in Group 2, while in Group 1 patients there was a statistically significant increase in creatinine clearance (+23% after 3 months, +31% after 6 months)."( Long-term treatment of chronic renal insufficiency with Ibopamine (SB 7505), a new orally active dopamine-related drug.
Colí, L; Docci, D; Mosconi, G; Prandini, R; Stefoni, S; Vangelista, A, 1982
)
1.23
"Ibopamine-treatment, which resulted in peak plasma epinine concentrations of 4-5 nmol.l-1, neither affected resting heart rate or blood pressure, nor any of the alpha- or beta-adrenoceptor parameters measured."( Lack of desensitization of alpha- and beta-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist.
Boomsma, F; Brodde, OE; Klusmann, I; Man in't Veld, AJ; Michel, MC; Wojcik, M, 1993
)
1.22

Toxicity

Long-term treatment with ibopamine affords an increase in survival and a delay in the progression of the disease, without adverse effects on cardiac rhythm and myocardial oxygen balance. It is concluded that Ibopamine is a safe drug which may become an interesting alternative or additive therapy for patients with chronic heart failure.

ExcerptReferenceRelevance
" The results rather suggest that long-term treatment with ibopamine affords an increase in survival and a delay in the progression of the disease, without adverse effects on cardiac rhythm and myocardial oxygen balance, and with a general improvement in the patients' quality of life."( Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results.
Cesana, B; Ferrari, V; Licciardello, L; Sher, D; Sirtori, F, 1991
)
0.93
" It is concluded that ibopamine is a safe drug which may become an interesting alternative or additive therapy for patients with chronic heart failure."( The safety profile of ibopamine, an alternative substance for treatment of chronic heart failure.
Holubarsch, C; Just, H, 1990
)
0.91
" does not affect metabolic control and lipid pattern in type II diabetic patients, therefore representing a safe tool for the treatment of chronic heart failure in these patients."( Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study.
Cicchetti, V; DiCarlo, A; Giannarelli, R; Marchetti, P; Navalesi, R; Sabino, F, 1990
)
0.68

Pharmacokinetics

The pharmacokinetic and pharmacodynamic interactions between single oral doses of 200 mg ibopamine and a standard cold 3100 kJ meal were assessed in 12 normal male subjects, who were studied on 4 occasions. When compared with the fasting state, Cmax and AUC0-3h were significantly reduced when ibopamines was given immediately after or 2 h after a meal. The behaviour of ibopamina in these patients was similar to that observed in a group of healthy volunteers.

ExcerptReferenceRelevance
" The hemodynamic studies using Swan-Ganz catheter and pharmacokinetic studies were carried out."( Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure.
Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992
)
0.52
"The pharmacokinetic and pharmacodynamic interactions between single oral doses of 200 mg ibopamine and a standard cold 3100 kJ meal were assessed in 12 normal male subjects, who were studied on 4 occasions, receiving either ibopamine or matched placebo (double-blind) in fasting condition or at the end of a meal."( Pharmacokinetic and pharmacodynamic interactions between single oral doses of ibopamine and food in normal man.
de Mey, C; Enterling, D; Meineke, I, 1989
)
0.73
" Furthermore, ibopamine-quinidine pharmacokinetic interaction and the effects of food on plasma kinetics were evaluated in NS."( Clinical pharmacokinetics of ibopamine on different diseases and conditions.
Lodola, E; Ventresca, GP, 1988
)
0.93
" No significant differences in the mean pharmacokinetic parameters of either drug were seen between the single and combined doses."( Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man.
Brendel, E; de Mey, C; Enterling, D; Wesche, H, 1988
)
0.52
" Free epinine pharmacokinetic parameters did not show any appreciable differences among the groups with different degrees of renal impairment, and no statistically significant differences were observed between normal subjects and CRI patients."( Pharmacokinetics of ibopamine in patients with renal impairment.
Bovio, G; Longo, A; Pataccini, R; Pocchiari, F; Salvadeo, A; Ventresca, GP; Villa, G, 1988
)
0.6
" When compared with the fasting state, Cmax and AUC0-3h were significantly reduced when ibopamine was given immediately after or 2 h after a meal."( Ibopamine (SK&F 100168) pharmacokinetics in relation to the timing of meals.
Buller, NP; Cregeen, RJ; Locke-Haydon, J; Pready, NS; Scott, SC, 1987
)
1.94
" The pharmacokinetic behaviour of ibopamine in these patients was similar to that observed in a group of healthy volunteers."( Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure.
Colombo, G; De Vita, C; Devizzi, S; Palvarini, M; Pataccini, R; Pocchiari, F; Triulzi, E, 1986
)
0.78
" In the present study, we have investigated the pharmacokinetic and pharmacodynamic characteristics of ibopamine after ocular application."( Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent.
Galbiati, I; Gazzaniga, A; Gianesello, V; Soldati, L; Virno, M, 1993
)
0.74

Bioavailability

Ibopamine is well absorbed through the cornea, it is rapidly hydrolysed by esterases to epinine. The relative bioavailability and bioequivalence of 3 oral presentations of Ibopamine was examined after a single oral dose.

ExcerptReferenceRelevance
" The compound was well absorbed in both species when given orally."( Identification of ibopamine metabolites in rat and dog urine.
Hwang, BY; Kuo, GY; Lynn, RK,
)
0.47
" The relative bioavailability and bioequivalence of 3 oral presentations of Ibopamine was examined after a single oral dose."( Study of the bioequivalence of three oral formulations of ibopamine in healthy volunteers.
Deger, F; Derenne, F; Douchamps, J; Herchuelz, A; Juvent, M; Seth, A; Vanschoubroek, K, 1988
)
0.75
" Ibopamine is well absorbed through the cornea, it is rapidly hydrolysed by esterases to epinine and the mydriatic effect is correlated with the concentration of epinine in the aqueous humor."( Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent.
Galbiati, I; Gazzaniga, A; Gianesello, V; Soldati, L; Virno, M, 1993
)
1.44

Dosage Studied

The pharmacokinetics of ibopamine after single and multiple dosing was studied in 20 patients with congestive heart failure (CHF) of NYHA functional class II. As the kinetics of Ibopamine's active moiety, free epinine, were not apparently altered by chronic renal failure, adjustment of its dosage should not be necessary.

ExcerptRelevanceReference
" Epinine is intensively metabolized so that less than 1% of the oral dosage is eliminated via the kidneys."( [Ibopamine--pharmacologic principles].
Borchard, U, 1991
)
1.19
" No change in diet or in the previous dosage of the antidiabetic drugs occurred during the study in any patient."( Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study.
Cicchetti, V; DiCarlo, A; Giannarelli, R; Marchetti, P; Navalesi, R; Sabino, F, 1990
)
0.68
" A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug."( Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Hasenfuss, G; Just, H, 1989
)
0.28
") shifted the dose-response curves for the positive inotropic effect of plasma-dissolved (PD) ibopamine (0."( Analysis of the positive inotropic effect of ibopamine in the blood-perfused canine papillary muscle.
Inui, J; Kawahara, K,
)
0.61
" The subjects were furthermore profiled in detail up to 4 h after dosing by transthoracic impedance cardiography."( Pharmacokinetic and pharmacodynamic interactions between single oral doses of ibopamine and food in normal man.
de Mey, C; Enterling, D; Meineke, I, 1989
)
0.51
" After the administration of SK&F R-83566, the renal vasodilator responses to fenoldopam were antagonized markedly with an approximate 30-fold rightward shift in the log dose-response curve, whereas the renal vasodilator responses to dopamine were abolished completely and converted into small vasoconstrictor responses."( Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
Nichols, AJ; Ruffolo, RR; Shebuski, RJ; Smith, JM, 1987
)
0.52
" The studies after single and multiple dosing were conducted in CHF patients."( Clinical pharmacokinetics of ibopamine on different diseases and conditions.
Lodola, E; Ventresca, GP, 1988
)
0.57
"The pharmacokinetics of ibopamine after single and multiple dosing was studied in 20 patients with congestive heart failure (CHF) of NYHA functional class II."( Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure.
Azzollini, F; De Caro, L; Lodola, E; Longo, A; Pelosi, G; Rolandi, E; Ventresca, GP, 1988
)
2.02
"As part of preclinical safety testing for carcinogenicity, postpubertal (50 days old) rats were dosed (0, 30, 90 or 180 mg/kg/day) with ibopamine (N-methyldopamine, 0,0'-diisobutyroyl ester."( Reduced disease in aged rats treated chronically with ibopamine, a catecholaminergic drug.
Walker, RF; Weideman, CA; Wheeldon, EB,
)
0.58
" Examination of the dose-response curves for epinine and ibopamine showed epinine to be 3- to 4-fold more potent than ibopamine with respect to increasing coronary blood flow, left ventricular stroke work, left ventricular dP/dt and rate-pressure product."( Systemic and coronary hemodynamic actions of the novel inotropic agent, ibopamine, and the de-esterified metabolite and active form, epinine: relationship to left ventricular performance in the dog.
Kopia, GA; Ohlstein, EH; Ruffolo, RR, 1988
)
0.75
" As the kinetics of ibopamine's active moiety, free epinine, were not apparently altered by chronic renal failure, adjustment of its dosage should not be necessary in renal diseases."( Pharmacokinetics of ibopamine in patients with renal impairment.
Bovio, G; Longo, A; Pataccini, R; Pocchiari, F; Salvadeo, A; Ventresca, GP; Villa, G, 1988
)
0.92
" Blood samples taken immediately before and at intervals for 3 h after dosing were analysed for free epinine."( Ibopamine (SK&F 100168) pharmacokinetics in relation to the timing of meals.
Buller, NP; Cregeen, RJ; Locke-Haydon, J; Pready, NS; Scott, SC, 1987
)
1.72
" The patients were randomly divided into two groups: 96 took ibopamine at a dosage of 100 mg/day (group A) and 93 served as controls (group B)."( Low-dosage ibopamine treatment in progressive renal failure: a long-term multicentre trial.
Bazzato, G; Bignamini, AA; Bonomini, M; Bonomini, V; Brancaccio, D; Cappelli, P; Cossu, M; De Biase, V; Docci, D; Fanciulli, E; Feletti, C; Fracasso, A; Galmozzi, C; La Manna, G; Locatelli, F; Marai, P; Mioli, V; Mosconi, G; Oldrizzi, L; Piccoli, G; Roccatello, D; Scarpioni, L; Sorba, GB; Stefoni, S; Sverzellati, E, 1996
)
0.93
"6) was examined to evaluate the dose-response effect and time course on pupil diameter, of ibopamine, phenylephrine, and tropicamide."( Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment.
Babighian, S; Bonomi, L; Marchini, G; Perfetti, S; Tosi, R, 2003
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
benzoate esterEsters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (287)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990131 (45.64)18.7374
1990's120 (41.81)18.2507
2000's26 (9.06)29.6817
2010's9 (3.14)24.3611
2020's1 (0.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.89 (24.57)
Research Supply Index6.00 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index39.89 (26.88)
Search Engine Supply Index2.48 (0.95)

This Compound (25.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials87 (27.71%)5.53%
Reviews38 (12.10%)6.00%
Case Studies13 (4.14%)4.05%
Observational1 (0.32%)0.25%
Other175 (55.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]